Who Generates More Revenue? Grifols, S.A. or Telix Pharmaceuticals Limited

Grifols vs. Telix: A Decade of Revenue Growth

__timestampGrifols, S.A.Telix Pharmaceuticals Limited
Wednesday, January 1, 2014335538400028336824
Thursday, January 1, 2015393456300032319194
Friday, January 1, 2016404983000029404631
Sunday, January 1, 2017431807300031769230
Monday, January 1, 2018448672400020439380
Tuesday, January 1, 2019509869100024186536
Wednesday, January 1, 202053400380004680000
Friday, January 1, 202149331180004898000
Saturday, January 1, 20226063967000155984000
Sunday, January 1, 20236591977000496659000
Loading chart...

Unleashing the power of data

Revenue Showdown: Grifols, S.A. vs. Telix Pharmaceuticals Limited

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of success. Over the past decade, Grifols, S.A. has consistently outperformed Telix Pharmaceuticals Limited in terms of revenue. From 2014 to 2023, Grifols' revenue surged by nearly 97%, reaching a peak in 2023. In contrast, Telix Pharmaceuticals, while showing growth, had a more modest increase, with its revenue in 2023 being approximately 17 times higher than in 2014.

Grifols' dominance is evident, with its revenue in 2023 being over 13 times that of Telix. This stark difference highlights Grifols' established market presence and strategic growth initiatives. As the industry evolves, it will be intriguing to see how Telix leverages its recent growth spurt to challenge Grifols' supremacy. Stay tuned for more insights into the dynamic world of pharmaceuticals.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025